Synapse - Alex Makhnin

Results (19)

A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung cancer

Journal Article

Choudhury, N. J.; Lai, W. V.; Makhnin, A.; Heller, G.; Eng, J.; Li, B.; Preeshagul, I.; Santini, F. C.; Offin, M.; Ng, K.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

Phase II study of cabozantinib in patients with MET-altered lung cancers

Meeting Abstract

Harada, G.; Santini, F. C.; Repetti, R. W.; Chang, J.; Yang, S. R.; Lin, Y. T.; Moses, K. A.; Falcon, C.; Wilhelm, C. J.; Goldstein, M.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Brief report: Combination of osimertinib and dacomitinib to mitigate primary and acquired resistance in EGFR-mutant lung adenocarcinomas

Journal Article

Elkrief, A.; Makhnin, A.; Moses, K. A.; Ahn, L. S.; Preeshagul, I. R.; Iqbal, A. N.; Hayes, S. A.; Plodkowski, A. J.; Paik, P. K.; Ladanyi, M.; more...
Clinical Cancer Research (2023)

Fulltext@MSK | Save

Tumor volume as a predictor of cell free DNA mutation detection in advanced non-small cell lung cancer

Journal Article

Haseltine, J. M.; Offin, M.; Flynn, J. R.; Zhang, Z.; Lebow, E. S.; Aziz, K.; Makhnin, A.; Eichholz, J.; Lim, L. P.; Li, M.; more...
Translational Lung Cancer Research (2022)

Fulltext@MSK | Save

Multiplex SuperSelective PCR assays for the detection and quantitation of rare somatic mutations in liquid biopsies

Journal Article

Vargas, D. Y.; Tyagi, S.; Marras, S. A. E.; Moerzinger, P.; Abin-Carriquiry, J. A.; Cuello, M.; Rodriguez, C.; Martinez, A.; Makhnin, A.; Farina, A.; more...
Journal of Molecular Diagnostics (2022)

Fulltext@MSK | Save

Erlotinib and trametinib in patients with EGFR-mutant lung adenocarcinoma and acquired resistance to a prior tyrosine kinase inhibitor

Journal Article

Luo, J.; Makhnin, A.; Tobi, Y.; Ahn, L.; Hayes, S. A.; Iqbal, A.; Ng, K.; Arcila, M. E.; Riely, G. J.; Kris, M. G.; more...
JCO Precision Oncology (2021)

Fulltext@MSK | Save

Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions

Journal Article

Mondaca, S.; Lebow, E. S.; Namakydoust, A.; Razavi, P.; Reis-Filho, J. S.; Shen, R.; Offin, M.; Tu, H. Y.; Murciano-Goroff, Y.; Xu, C.; more...
Lung Cancer (2021)

Fulltext@MSK | Save

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

Journal Article

Poels, K. E.; Schoenfeld, A. J.; Makhnin, A.; Tobi, Y.; Wang, Y.; Frisco-Cabanos, H.; Chakrabarti, S.; Shi, M.; Napoli, C.; McDonald, T. O.; more...
Nature Communications (2021)

Fulltext@MSK | Save

MET exon 14-altered lung cancers and MET inhibitor resistance

Journal Article

Guo, R.; Offin, M.; Brannon, A. R.; Chang, J.; Chow, A.; Delasos, L.; Girshman, J.; Wilkins, O.; McCarthy, C. G.; Makhnin, A.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: A phase 1/2 single-group open-label trial

Journal Article

Yu, H. A.; Schoenfeld, A. J.; Makhnin, A.; Kim, R.; Rizvi, H.; Tsui, D.; Falcon, C.; Houck-Loomis, B.; Meng, F.; Yang, J. L.; more...
JAMA Oncology (2020)

Fulltext@MSK | Save